French drug firm Sanofi said its speciality care global business unit Sanofi Genzyme has launched its multiple sclerosis (MS) treatment drug Aubagio in India. The drug offers patients diagnosed with multiple sclerosis the efficacy and convenience of once-a-day oral treatment, Sanofi Genzyme said in a statement. N. Rajaram, Sanofi India MD, said: “For over a decade Sanofi has invested in developing and delivering novel therapeutic solutions for the treatment of multiple sclerosis around the world; and is now bringing Aubagio, our original research product to India.” He added this product has the potential to offer an efficacious and convenient treatment regimen of just once a day oral tablet, vis-a-vis commonly available injectable treatment options. Shalini Menon, Country Medical Director, Sanofi South Asia, said: “Aubagio is a differentiated disease-modifying therapy, that blocks the enzyme involved in multiplication of overactive immune cells.” Approved by the USFDA in 2012, Aubagio currently has a global presence with approvals in more than 81 countries, the statement said.